Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8501730 | OTSUKA | Process for preparing benzazepine compounds or salts thereof |
Sep, 2026
(3 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10905694 | OTSUKA | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Apr, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 23, 2025 |
Market Authorisation Date: 23 April, 2018
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8501730 | OTSUKA | Process for preparing benzazepine compounds or salts thereof |
Sep, 2026
(3 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10905694 | OTSUKA | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Apr, 2030
(7 years from now) |
Market Authorisation Date: 19 May, 2009
Treatment: NA
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic